Tiffany Thorn is the Founder of BiVictriX Therapeutics plc and is the inventor of the Bi-Cygni® approach, a novel concept which originated from her previous experience as a clinician supporting the diagnosis of haematological malignancies. Ms Thorn has led BiVictriX since its formation in 2016, meeting key corporate milestones and securing c.£10m in investment to date, including leading the successful IPO of the Company onto the London Stock Exchange’s AIM market in August 2021.

Ms Thorn brings a strong background in the ADC sector having held senior management positions at ADC-sector specialist, ADCBio Ltd (now Sterling Pharma Solutions), coupled with direct clinical experience from within the NHS. Ms Thorn trained and qualified as a HCPC-registered Clinical Immunologist at Manchester Royal Infirmary and Preston Royal Hospital, UK and during this time was awarded “NHS England’s Chief Scientific Officer’s Rising Star Award” for her commitment to facilitating better healthcare by strengthening the links between the UK’s healthcare sector and the biotech industry.

Ms Thorn graduated with a First-Class Honours Degree in Biochemistry with Biomedicine from Lancaster University and obtained an MSc in Clinical Immunology from the University of Manchester.

Dr. Oliver Schon is VP, Product Development & CMC at BiVictriX Therapeutics plc, bringing over 20 years of experience in antibody discovery and manufacture. Dr. Schon obtained his PhD in Cancer Research from The University of Cambridge before joining Sir Gregory Winter’s domain-antibody biotech venture Domantis Ltd in 2003 which was acquired by GSK three years later. Dr Schon continued to work at GSK for over ten years dedicated to developing biologics and cell therapy platforms for use in the clinic until he joined IO-focussed American biotech Agenus Inc in 2017; it was here that he amassed considerable CMC and biologics-based therapeutics manufacturing experience, developing numerous bispecific antibodies from discovery up until Investigational New Drug application (IND) and beyond.

At BiVictriX, Dr. Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bispecific therapeutic ADC candidates to clinical development.

Glyn Baker is Chief Financial Officer at BiVictriX Therapeutics plc, bringing over 20 years of experience in senior financial management roles across the biotech sector. Mr Baker was previous Chief Financial Officer at TwistDx Ltd, a Cambridge UK based start-up, which developed an Isothermal Amplification alternative to PCR for point of care and over the counter molecular testing products. TwistDx were sold to Alere Inc, who were subsequently acquired by Abbott Laboratories. More recently, Mr Baker guided Inflazone Ltd, in his role as Finance Director, through a €40m Series B funding round and eventual exit to Roche Pharmaceuticals for an upfront payment of $450m plus substantial milestones

At BiVictriX, Mr Baker is responsible for maintaining strong internal financial controls, regulatory filings and investor relations.

Dr. Kevin Moulder is Chief Scientific Officer at BiVictriX Therapeutics plc, bringing over 30 years of experience in drug discovery and development. Dr. Moulder has previously served in senior R&D leadership positions across 9 international biotechnology companies, including Biogen. He has previously held the position of Chief Scientific Officer at bispecific antibody company, F-Star Therapeutics Inc and held several C-level positions at Medicenna Therapeutics Corp and PolyProx Therapeutics Ltd. Dr. Moulder was previously Chief Development Officer at UK-based immuno-oncology company Tusk Therapeutics Ltd, which was later acquired by Roche Pharmaceuticals in a deal valued up to $759m. He was also previous VP of Research at Sir Gregory Winter’s biotech venture Domantis Ltd, leading the creation of a pipeline of novel single domain antibodies and ultimately resulting in its acquisition by GSK three years later.

At BiVictriX, Dr. Moulder is applying his broad knowledge of the bispecific antibody and immuno-oncology sector to expedite the development of the Company’s broad pipeline of therapeutic assets towards the clinic.

Tiffany Thorn is the Founder of BiVictriX Therapeutics plc and is the inventor of the Bi-Cygni® approach, a novel concept which originated from her previous experience as a clinician supporting the diagnosis of haematological malignancies. Ms Thorn has led BiVictriX since its formation in 2016, meeting key corporate milestones and securing c.£10m in investment to date, including leading the successful IPO of the Company onto the London Stock Exchange’s AIM market in August 2021.

Ms Thorn brings a strong background in the ADC sector having held senior management positions at ADC-sector specialist, ADCBio Ltd (now Sterling Pharma Solutions), coupled with direct clinical experience from within the NHS. Ms Thorn trained and qualified as a HCPC-registered Clinical Immunologist at Manchester Royal Infirmary and Preston Royal Hospital, UK and during this time was awarded “NHS England’s Chief Scientific Officer’s Rising Star Award” for her commitment to facilitating better healthcare by strengthening the links between the UK’s healthcare sector and the biotech industry.

Ms Thorn graduated with a First-Class Honours Degree in Biochemistry with Biomedicine from Lancaster University and obtained an MSc in Clinical Immunology from the University of Manchester.

Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and, in addition to BiVictriX, Mr Ross is currently Chairman of Silence Therapeutics plc (LSE/NASDAQ), ReNeuron Group plc (AIM: RENE) and Kazia Therapeutics Limited (ASX/NASDAQ). He was previously Chairman of Redx Pharma plc from 2017 until June 2021.

Mr Ross has completed multiple financing transactions and has over 30 years of experience in cross-border management as a chairman and CEO. He has led and participated in seven IPOs and has direct experience in M&A transactions in Europe, the USA and the Pacific Rim.

During his career, Mr Ross has held senior positions at multinational companies including, Sandoz AG, Hoffman La Roche, and Celltech Group plc. He has a BSc (Biochemistry) from London University, is a qualified Chartered Director and is a former Vice Chairman of the Council of Royal Holloway, London University.

Prof. Robert Hawkins brings over 20 years of experience in medical oncology and the development and utilisation of advanced therapies in the oncology sector. He is the scientific founder of Instil Bio (NASDAQ: TIL), which raised $368m during an IPO onto NASDAQ in March 2021 and has a market capitalisation of $2bn (August 2021).

Prof. Hawkins was a founding consultant of Cambridge Antibody Technology, which was acquired by AstraZeneca in 2006, and was a founding consultant of Oxford Biomedica plc. He was formerly a Cancer Research UK Professor at the University of Manchester and remains a practicing Medical Oncologist at the Christie Hospital in the UK. Over his career, Prof. Hawkins has had multiple scientific/clinical advisory board positions within big pharma and large biotech companies.

Professor Hawkins received his MB BS from University College, London and was awarded an MRC training fellowship to work with Sir Gregory Winter at the Laboratory of Molecular Biology in Cambridge, from where he obtained a PhD in antibody engineering. He trained in Medical Oncology at the Royal Marsden Hospital, London and Addenbrookes Hospital, Cambridge.

Dr. Michael Kauffman has over 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development and regulatory strategy. In addition to BiVictriX, he is a board member for Verastem Oncology, Adicet Bio and Kezar Life Sciences.

Dr. Kauffman previously served as Co-Founder and Chief Executive Officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial stage organisation and latterly served as Senior Medical Advisor. Dr. Kauffman was previous Chief Medical Officer of Onyx Pharmaceuticals Inc. and was previously President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.).

Dr. Kauffman was the leader of the Velcade® development program at Millennium Pharmaceuticals, and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School, trained at Beth Israel and Massachusetts General Hospitals in Boston and is board certified in Internal Medicine.

Susan Lowther brings over 30 years of experience in senior financial leadership roles across a broad range of public and private life science companies. Ms Lowther currently serves as Chief Financial Officer and Company Secretary at Arecor Therapeutics plc, which raised £20m in June 2021 during a successful IPO onto the London Stock Exchange’s AIM market.

Ms Lowther was formerly Chief Financial Officer and Company Secretary at IXICO plc, an imaging contract research organisation, and has previously held several senior finance roles, including at Novacyt SA, BioWisdom Ltd and Lab21 Group.

Drummond Paris brings over 40 years of experience in senior management roles in the pharmaceutical and life sciences industries. Mr Paris previously spent eight years as President of Kowa Research and Kowa Pharmaceuticals Europe Ltd and held several leadership positions in Novartis at country, regional and global levels.

Mr Paris was previously the non-executive Chairman of Karus Therapeutics Ltd, Electrospinning Company Ltd and Sirigen (now part of Becton Dickinson).